Full-Time

Senior Director

Sales Training and Development

Posted on 6/27/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$225k - $255kAnnually

+ Annual Bonus + Equity

Senior

New York, NY, USA

On-site requirement of at least three days per week.

Category
Customer Success Management
Sales & Account Management
Requirements
  • Bachelor’s Degree Required
  • 7+ years in Leadership/Organizational training in the pharmaceutical industry
  • 10+ years of previous pharmaceutical, biotech, or medical/marketing/sales/training experience with a strong knowledge of the pharmaceutical marketplace and deep understanding of the pharmaceutical industry
  • Up to 30% travel
  • Ability to work on-site Monday, Tuesday, and Thursday. We are unable to consider candidates who are looking for fully remote roles
Responsibilities
  • Spearhead Axsome’s learning and development strategy, creating a roadmap, and implementing programs that cultivate the necessary talent and skills to achieve our strategic long-term objectives across a diverse portfolio of innovative products
  • Lead and manage a training team, providing guidance, mentorship, and support. Fostering a collaborative environment that encourages skill development and knowledge sharing
  • Oversee the planning and development of workshops, both at the national and regional levels. Conduct 'train-the-trainer' sessions to empower internal trainers with the necessary skills to deliver effective training
  • Take the leading role in the development and execution of frontline sales leader training and development initiatives
  • Ensure seamless integration of training materials and assessments within the LMS
  • Collaborate with cross-functional partners, including Medical, Regulatory, and Legal teams, to support development, approval and execution of training programs and resources, ensuring compliance with company policy as well as industry regulations and guidelines
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's AXS-05 has FDA Breakthrough Therapy Designation, expediting its development.
  • Increased investment in CNS research offers potential partnerships for Axsome.
  • Rising demand for non-opioid pain management aligns with Axsome's novel therapies.

What critics are saying

  • Departure of key personnel like Lori Englebert may impact strategic direction.
  • Increased competition in CNS disorder treatments could challenge Axsome's market position.
  • Reliance on flagship products like AXS-05 increases vulnerability to regulatory challenges.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs in this area.
  • The company develops novel therapies like AXS-05 for major depressive disorder.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE